ICICI Prudential Healthcare Fund-Growth
The fund is rated 4 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Higher annual fee of 2.07% and above-average fund size of Rs 6,802.61 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 6802.61 AUM and a 2.07 expense ratio. Considering all these factors, we have rated this fund as 4.0 star.
અમારો સ્કોર લાંબા ગાળાની કામગીરી, જોખમ અને સાતત્યને વજન આપે છે — ફક્ત ભૂતકાળના વળતરને નહીં.
રિટર્ન
21 Sep 2026 મુજબ
જોખમ ગુણોત્તર
31 Aug 2026 મુજબ
પોર્ટફોલિયો
31 Aug 2026 મુજબ
માર્કેટ-કેપ વિભાજન
સેક્ટર ફાળવણી
હોલ્ડિંગ્સ (36)
| હોલ્ડિંગ | ફંડનો % | મૂલ્ય | શેર |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 12.31% | ₹861.02 Cr | 43,38,091 |
| Dr. Reddy's Laboratories Ltd. | 8.26% | ₹578.12 Cr | 50,08,009 |
| Cipla Ltd. | 5.76% | ₹402.74 Cr | 28,57,946 |
| Mankind Pharma Ltd. | 5.21% | ₹364.6 Cr | 15,07,093 |
| Alkem Laboratories Ltd. | 4.87% | ₹340.98 Cr | 6,39,791 |
| Divi's Laboratories Ltd. | 4.83% | ₹337.57 Cr | 3,56,579 |
| Others | 4.78% | ₹334.29 Cr | — |
| Biocon Ltd. | 4.68% | ₹327.26 Cr | 79,43,167 |
| Medplus Health Services Ltd. | 4.15% | ₹290.26 Cr | 43,17,751 |
| Cohance Lifesciences Ltd. | 4.08% | ₹285.73 Cr | 62,66,692 |
ફંડ વિગતો
Long term wealth creation. An Equity Scheme that predominantly invests in Equity and Equity related securities of companies in Healthcare Sector.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Exit load of 1% if redeemed within 15 days.